98%
921
2 minutes
20
Objective: To investigate the expression of kinesin family member 20A (KIF20A) in bladder cancer, the effect of KIF20A on the proliferation and metastasis of bladder cancer cells, and the effect of KIF20A expression on the prognosis of bladder cancer patients.
Methods: Bladder cancer tissue and its adjacent tissues were collected from tumour patients. The mRNA and protein expression levels of KIF20A in the tissue samples were detected by qRT-PCR and western blot. Immunohistochemical (IHC) staining was used to identify the expression and distribution of KIF20A proteins in the tissue samples. The relationship between the KIF20A expression and the clinical pathology of bladder cancer was analysed. The effect of the differential expression of KIF20A on the prognosis of patients with bladder cancer was analysed by the TCGA database. The plasmid was transfected into the bladder cell lines T24 and 5637 to construct two stable cell lines with knocked down KIF20A. The effect of KIF20A expression on the proliferation and invasion of T24 and 5637 bladder cells was explored in vitro using the abovementioned stable cell lines. The effect of the KIF20A expression on the proliferation of bladder cancer cells was evaluated by a mouse xenograft model.
Results: The expression of KIF20A was significantly higher in the bladder cancer tissues than in the adjacent control tissues. The expression of KIF20A was significantly associated with the degree of pathological differentiation of bladder cancer. Patients with a higher expression of KIF20A had a higher tumour grade and a more advanced stage. The mean survival of patients with a high KIF20A expression was significantly lower than the mean survival of patients with a low KIF20A expression. The in vitro experiments demonstrated that the knockdown of KIF20A significantly inhibited T24 and 5637 cell proliferation and invasion. The in vivo experiments showed that the knockdown of KIF20A significantly inhibited the proliferation of the bladder tumours.
Conclusion: KIF20A promotes the proliferation and metastasis of bladder cancer cells. Bladder cancer patients with a high KIF20A expression have a worse tumour differentiation and a poor prognosis. KIF20A may become an independent factor that affects the prognosis of bladder cancer patients and a therapeutic target for bladder cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481133 | PMC |
http://dx.doi.org/10.1155/2019/4863182 | DOI Listing |
Biomed Rep
November 2025
College of Public Health, Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
flavones (PRFs), bioactive components derived from the plant, exhibit anti-inflammatory and anti-tumor properties. However, their therapeutic potential for bladder cancer remains poorly understood. The present study aimed to investigate the anti-tumor effects and molecular mechanisms underlying the effects of PRF on human bladder cancer T24 cells.
View Article and Find Full Text PDFAdv Radiat Oncol
October 2025
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology and Radiotherapy, Augustenburger Platz 1, 13353 Berlin, Germany.
Purpose: To evaluate the impact of an optimized online adaptive radiation therapy workflow on physician involvement.
Methods And Materials: Data from a prospective phase 2 trial involving 34 prostate cancer patients treated with cone beam computed tomography (CBCT)-based online adaptive radiation therapy (62 Gy in 20 fractions) were analyzed. Manual interventions were required for 2 steps in the workflow: radiation therapy technologist review and adjustment of automatically segmented organs, guiding target segmentation, so-called "influencer," while physicians reviewed and refined the targets.
Ther Adv Urol
September 2025
Department of Urology, Peking University People's Hospital, 11 Xizhimen South Street, Haidian District, Beijing 100044, China.
Objective: Many studies have stressed the necessity of repeat transurethral resection (reTURB) following the initial conventional transurethral resection of the bladder for non-muscle invasive bladder cancer (NMIBC) patients. However, there have been few studies focusing on the role of reTURB after en bloc resection of bladder tumor (ERBT) for NMIBC by far. This study aimed to evaluate whether reTURB can be avoided after ERBT.
View Article and Find Full Text PDFJ Appl Clin Med Phys
September 2025
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Purpose: This study aims to assess percentage of automated AIO plans that met clinical treatment standards of radiotherapy plans generated by the fully automated All-in-one (AIO) process.
Methods: The study involved 117 rectal cancer patients who underwent AIO treatment. Fully automated regions of interest (ROI) and treatment plans were developed without manual intervention, comparing them to manually generated plans used in clinical practice.
Curr Med Imaging
May 2025
Department of Radiology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Background: Predicting the recurrence risk of NMIBC after TURBT is crucial for individualized clinical treatment.
Objective: The objective of this study is to evaluate the ability of radiomic feature analysis of intratumoral and peritumoral regions based on computed tomography (CT) imaging to predict recurrence in non-muscle-invasive bladder cancer (NMIBC) patients who underwent transurethral resection of bladder tumor (TURBT).
Methods: A total of 233 patients with NMIBC who underwent TURBT were retrospectively analyzed.